The company operates without recurring revenue, reporting a net loss of $14.5 million in 2026Q1 while R&D expenses continue to escalate.
| Sales/Revenue | 0 | 0 | 0 | 50M | 0 | 0 |
| Revenue Growth % | - | - | -100% | - | - | - |
| Cost of Goods Sold | 79K | 0 | 258K | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | -79K | 0 | -258K | 50M | 0 | 0 |
| Gross Margin % | - | - | - | 100% | - | - |
| Gross Profit Growth % | - | 100% | -100.52% | - | - | - |
| Operating Expenses | 66.77M | 68.06M | 50.64M | 66.08M | 22.72M | 28.65M |
| OpEx % of Revenue | - | - | - | 132.15% | - | - |
| Selling, General & Admin | 17.39M | 16.54M | 12.47M | 6.32M | 5.83M | 6.29M |
| SG&A % of Revenue | - | - | - | 12.64% | - | - |
| Research & Development | 49.38M | 51.52M | 38.16M | 27.6M | 16.89M | 22.36M |
| R&D % of Revenue | - | - | - | 55.21% | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 32.15M | 0 | -91K |
| Operating Income | -66.85M | -68.06M | -50.89M | -16.08M | -22.72M | -28.65M |
| Operating Margin % | - | - | - | -32.15% | - | - |
| Operating Income Growth % | - | -33.73% | -216.56% | 29.24% | 20.69% | - |
| EBITDA | -66.53M | -67.74M | -50.64M | -15.88M | -22.39M | -28.32M |
| EBITDA Margin % | - | - | - | -31.76% | - | - |
| EBITDA Growth % | -254.75% | -33.77% | -218.83% | 29.07% | 20.94% | - |
| D&A (Non-Cash Add-back) | 328K | 323K | 258K | 195K | 329K | 325K |
| EBIT | -64.99M | -68.06M | -42.26M | 23.38M | -23.86M | -28.67M |
| Net Interest Income | 8.5M | 8.25M | 8.9M | 4.4M | 373K | -255K |
| Interest Income | 8.5M | 8.25M | 8.9M | 4.61M | 761K | 77K |
| Interest Expense | 0 | 0 | 0 | 208K | 388K | 332K |
| Other Income/Expense | 8.41M | 8.08M | 8.64M | 39.25M | -1.53M | -354K |
| Pretax Income | -58.44M | -59.98M | -42.26M | 23.17M | -24.25M | -29M |
| Pretax Margin % | - | - | - | 46.34% | - | - |
| Income Tax | 0 | 0 | 0 | 450K | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 1.94% | 0% | 0% |
| Net Income | -58.44M | -59.98M | -42.26M | 22.72M | -24.25M | -29M |
| Net Margin % | - | - | - | 45.44% | - | - |
| Net Income Growth % | -17.28% | -41.93% | -285.99% | 193.68% | 16.37% | - |
| Net Income (Continuing) | -58.44M | -59.98M | -42.26M | 22.72M | -24.25M | -29M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.57 | -2.17 | -1.63 | 0.13 | -0.97 | -1.15 |
| EPS Growth % | -1.04% | -33.13% | -1353.85% | 113.4% | 15.65% | - |
| EPS (Basic) | - | -2.17 | -1.63 | 0.13 | -0.97 | -1.15 |
| Diluted Shares Outstanding | 37.34M | 27.7M | 25.85M | 25.13M | 25.13M | 25.13M |
| Basic Shares Outstanding | 37.34M | 27.7M | 25.85M | 25.13M | 25.13M | 25.13M |
| Dividend Payout Ratio | - | - | - | - | - | - |
Clinical trial execution dependency
As reported in financial statements, Contineum's R&D expenditures have trended upward, reaching $11.6 million in 2026Q1, which underscores the capital-intensive nature of advancing its dual-asset pipeline through mid-stage clinical trials without the benefit of recurring revenue to offset these significant operational outlays.
The company's cost structure is almost entirely dominated by R&D, reflecting the necessary investment in clinical trial execution and specialized scientific personnel. Investors should monitor whether these costs stabilize as trials progress or if the complexity of CNS-penetrant molecule development necessitates further increases in expenditure.
Based on Contineum's reported figures, stock-based compensation has become a consistent non-cash expense, totaling $3.8 million in 2026Q1 alone, which effectively masks the true operational burn rate and introduces potential dilution concerns for shareholders as the company seeks to retain specialized talent.
The reliance on equity-based incentives is common for clinical-stage biotech, yet the magnitude relative to the company's cash position warrants scrutiny. This practice suggests that the reported net loss may understate the actual economic cost of operations, potentially impacting future per-share value.
According to recent SEC filings, Contineum maintains a clean balance sheet with minimal debt, yet the absence of revenue means that operating leverage is currently non-existent, leaving the company entirely dependent on external capital or milestone payments to fund its ongoing clinical development programs.
The lack of revenue generation means that every dollar of SG&A and R&D directly impacts the cash runway. Without a commercial product, the company cannot achieve operating leverage, making the timing of J&J partnership milestones the primary determinant of financial stability.
As indicated by the income statement's persistent losses, the company's valuation is tethered to the success of PIPE-791 and PIPE-307, where any clinical setback could render the current cost structure unsustainable and force a rapid, potentially dilutive, search for additional liquidity.
Short-term observers may focus on the $75.6 million cash position as a buffer, but this figure is highly sensitive to trial enrollment velocity and CRO costs. The reliance on a narrow pipeline suggests that the company's financial health is more fragile than the current cash balance might imply.
Quick answers to the most common questions about buying CTNM stock.
For fiscal year 2025, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) reported total revenue of $0.0M.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) reported a net loss of $60.0M for the fiscal year ending 2025.